See also stories tagged with Oncology
A new study using mass spectrometry is helping piece together what happens when DNA that has been sensitized by the oncology drug 5-fluorouracil is subjected to the ionising radiation used in radiotherapy.
Biomedical engineers at Duke University have devised a method for increasing the resolution of optical coherence tomography (OCT) down to a single micrometer in all directions, even in a living patient. The new technique, ...
Carbon nanoparticles are a promising tool for biomedical applications, for example, for targeted transportation of biologically active compounds into cells. A team of researchers from the Physics, Medicine and Chemistry departments ...
A major challenge for cancer surgeons is to determine exactly where a tumor starts and where it ends. Removing too much tissue can impair normal functions, but not taking enough can mean the disease could recur. The "MasSpec ...
Marek's disease—a highly contagious viral disease caused by a herpesvirus—is a constant threat to poultry worldwide. It is also one of the most preventable diseases with vaccination. However, while vaccines prevent poultry ...
Chemists funded by the SNSF have created a new compound for flexible drug delivery that specifically targets prostate cancer cells. Incorporating four different molecules, the compound prevents tumor cells from multiplying, ...
A pioneering new technique that could make light-based cancer treatment more effective and safer for patients, while reducing its cost, has been developed by researchers from the University of Sheffield.
Pfizer announced Monday it will merge its off-patent drug business with generic drugmaker Mylan to create a global leader in low-cost treatment, a business that faces significant political pressure in the US.
Specialists at the National Research Nuclear University MEPhI and institutional collaborators have proposed a concept of hypersensitive sensory transducers (Fourier nano transducers) that could drastically revolutionise ultrasensitive ...
A scientific team from a small innovative enterprise, Biomimetix, based at the National University of Science and Technology MISIS together with their colleagues from the N.N. Blokhin National Medical Research Centre of oncology ...
